News and Trends 18 Aug 2022 FDA lifts partial clinical hold on Curis lymphoma study Curis, Inc., a biotech company focused on the development of innovative therapeutics for the treatment of cancer, says the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim lymphoma phase 1/2 study of emavusertib after reviewing the data package submitted by Curis. “We are excited to announce that FDA […] August 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2022 CSL gets positive results for preventive treatment in patients with hereditary angioedema Hereditary angioedema (HAE), a condition that causes recurrent attacks of severe swelling, could be prevented by a monoclonal antibody after positive top line phase 3 results were reported. Garadacimab, biotech company CSL’s investigational monoclonal antibody inhibiting factor XIIa, is being developed as a long-term preventive treatment for patients with HAE. Efficacy objectives The study met […] August 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 Sanofi drops amcenestrant clinical development program Sanofi says it is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision was based on the outcome of an interim analysis of the phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive […] August 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Viridian reports positive news from ongoing trial for patients with Thyroid Eye Disease Patients with active thyroid eye disease (TED) could benefit from rapid and significant improvements after positive data emerged from a clinical trial. Viridian Therapeutics made the announcement yesterday (August 15) that the 10mg/kg cohort in its ongoing phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody TED – an autoimmune disease where the body’s own immune […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies The first patient has been dosed in a phase 1 trial evaluating a monotherapy treatment in people with advanced solid tumors and hematologic malignancies in Australia. Antengene Corporation Ltd., is running the ATRIUM trial, a phase 1 multi-center, open-label, dose-finding study of monotherapy ATG-018. Safety and tolerability of ATG-018 The primary objective of the study […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Gannex’ first patient dosed in study for treatment of primary biliary cholangitis A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Pneumagen embarks on phase 2 proof of concept influenza study Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […] August 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 First patient enrolled on Panbela’s trial for treatment of pancreatic cancer Panbela Therapeutics, a U.S.-based clinical stage company, announced today (August 11) that it has enrolled its first patient in a global trial to evaluate a potential cure for pancreatic cancer. The trial referred to as ASPIRE will involve studying SBP-101, a treatment for metastatic pancreatic ductal adenocarcinoma. It is a randomized, double-blind placebo-controlled, trial with […] August 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 Study of drug to treat porphyria disorders initiated by Disc Medicine A phase 2 clinical study of bitopertin in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) has been initiated by Disc Medicine. The announcement of the study, called BEACON, was made August 10. EPP or XLP belong to a group of the porphyria disorders, which are all characterized by abnormally high levels of chemicals, […] August 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Stem cell therapy to be used in treatment of long COVID by Panacell Biotech A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID. NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Bone Therapeutics and Medsenic set to combine in share for share deal Subject to the outcome of a shareholders’ meeting, Bone Therapeutics and Medsenic are set to combine their operations reducing risks and broadening portfolios. The companies announced they have signed a share for share binding contribution today (August 10) which will create new enterprise BioSenic. Brussels and Paris-based Bone Therapeutics is a cell therapy company that […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma A Polish biopharma company focused on treating cancer and autoimmune diseases announced today (August 10) that it has chosen a lead candidate for the treatment of hepatocellular carcinoma. The molecular glue candidate, CPT-6281 will be Captor Therapeutic’s CT-01 project which will initially focus on the clinical development of the asset as a targeted protein degradation […] August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email